Quetiapine augmentation in treatment-resistant depression: a naturalistic study.

Department of Psychiatry, Clinical Hospital Centre Zagreb, Kispatićeva 12, Zagreb, Croatia.
Psychopharmacology (Impact Factor: 3.99). 10/2006; 187(4):511-4. DOI: 10.1007/s00213-006-0452-x
Source: PubMed

ABSTRACT Treatment-resistant depression (TRD) is a common clinical problem, often complicated with suicidal ideations and greater lifetime functional impairment, and represents a considerable challenge to management and treatment.
The aim of a prospective, open-label, noncomparative, flexible-dosed 20-week study was to evaluate the effects of quetiapine, as an add-on therapy, in patients with TRD who were refractory to previous treatments.
Eighteen patients with major depressive disorder (DSM-IV criteria) were treated for 20 weeks with quetiapine (mean dose 315+/-109 mg/day). Patients were evaluated at baseline, weekly from 1 to 9 weeks, and then after 12, 16, and 20 weeks of treatment, using Hamilton rating scale for depression-17 items (HAMD) scale.
Fourteen patients with TRD completed the 20-week open trial with quetiapine. The augmentation with quetiapine significantly reduced total scores and scores listed in the anxiety subscale on the HAMD, and these effects were observed after the fourth week of treatment, while the depressed mood scores were significantly reduced after the fifth week of treatment. Quetiapine add-on treatment significantly decreased the scores listed in the insomnia subscale on the HAMD subscale after the second week of treatment.
Our preliminary data indicate that quetiapine add-on therapy appears to have beneficial effects in the treatment of patients with TRD.


Available from: Marina Sagud, Jul 03, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We conducted an electronic chart review of a sample of all people attending secondary mental health care, in the county of Lanarkshire, Scotland, who were commenced on quetiapine for the following mood disorders: non-psychotic depression (n = 171), psychotic depression (n = 39), bipolar mania (n = 24), bipolar depression (n = 38) and bipolar mixed states (n = 31), between 2002 and 2007. We retrospectively assigned severity and improvement Clinical Global Impression (CGI) scores to measure effectiveness. Quetiapine was co-prescribed with antidepressants in 75-97% of depressive disorders. Commencing quetiapine was associated with clinical improvement in >64% of all patients, median doses (200-400 mg/day). For all depressive subtypes (non-psychotic, psychotic and bipolar) quetiapine was associated with improvement in 69% of patients. Across CGI measures, bipolar mania patients had the best outcome (89% improved). In bipolar mania, higher maximum doses were associated with greater improvement and 45% were continued on antidepressants. The results should be interpreted with caution due to the observational nature of the study and findings may not be attributed to the effects of quetiapine alone. Quetiapine was used mainly as an adjunct to other antidepressant and mood stabilising agents. The pharmacological profile of quetiapine suggests its properties extend beyond antipsychotic action, to antidepressant, anxiolytic and mood stabilising effects.
    Journal of Psychopharmacology 04/2009; 24(4):565-72. DOI:10.1177/0269881108100774 · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Today though we have a large number of antidepressants, there are also a large number of patients who do not respond to traditional antidepressant therapy. Various augmentation strategies have been suggested in these cases the foremost being atypical antipsychotic therapy. In fact atypical antipsychotic drugs (aripiprazole and quetiapine) have received US FDA approval as augmenting agents in the treatment of major depression. The present review looks at the various studies of atypical antipsychotics in the management of depression along with efficacy amongst individual drugs. The various mechanisms that may result in antidepressant action by atypical antipsychotics have been discussed along with novel mechanisms that may play a role. The review concludes that atypical antipsychotics have a place in the pharmacotherapy of depression and are useful agents as both augmentation strategies and in the management of treatment resistant depression.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The hypothalamic-pituitary-adrenocortical (HPA) system is believed to play an important role in the pathophysiology of major depressive disorder. In this context, the atypical antipsychotic quetiapine (QUE) has been shown to inhibit HPA system activity in healthy subjects. In this study we investigated whether the putative inhibitory effects of QUE on HPA system activity may contribute to its antidepressant efficacy. We analyzed the effects of QUE as an augmentation to the selective serotonin reuptake inhibitor (SSRI) escitalopram (ESC) on HPA system activity in comparison to a monotherapy with ESC in relation to the antidepressant effectiveness. HPA axis activity (cortisol and ACTH) was measured by means of the dexamethasone/corticotropin-releasing hormone (DEX/CRH) test which was performed before (week 0) and during (week 1, week 5) antidepressant psychopharmacotherapy. The combination therapy, but not the ESC monotherapy showed significantly inhibiting effects on HPA system activity leading to stepwise down-regulation. ACTH concentrations were reduced in the ESC/QUE group during five weeks of treatment. The inhibitory effect of QUE may be involved in its antidepressant effects as an augmentation strategy.
    Journal of Psychiatric Research 05/2014; 52. DOI:10.1016/j.jpsychires.2014.01.013 · 4.09 Impact Factor